CD8A and COVID-19: demonstrated that a larger proportion of CD8+ T cell effectors with tissue-resident and highly expanded features were present in bronchoalveolar lavage fluid (BALF) from patients with moderate COVID-19 compared to patients with severe/critical infection (33).